RxDoctor Payments Data

Miriam Reyes, MD

Family Medicine · Louisville, KYNPI 1063412724

Payments from drug & device makers

$10,059in general payments, 2019–2025

Across 577 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Amgen$782
  • GSK$632
  • Pfizer$567
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$9,99799%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,059 in reported general payments places this provider in the 95th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$25,195
Medicare patients
84
Services billed
383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban26$33,660
OzempicSemaglutide22$33,290
MounjaroTirzepatide18$23,763
Repatha SureclickEvolocumab16$20,795
EliquisApixaban17$20,188
FarxigaDapagliflozin Propanediol19$18,880
JanuviaSitagliptin Phosphate12$14,273
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,382
MyrbetriqMirabegron14$6,297
SynthroidLevothyroxine Sodium36$2,954
Dexlansoprazole DrDexlansoprazole13$2,503
Arnuity ElliptaFluticasone Furoate12$2,330
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen85$2,113
Fenofibrate21$2,056
Levocetirizine Dihydrochloride145$1,925

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$275$33,66026 claims
Novo NordiskOzempic$1,157$33,29022 claims
Lilly USA, LLCMounjaro$353$23,76318 claims
PfizerEliquis$567$20,18817 claims
AstraZenecaFarxiga$1,621$18,88019 claims
MerckJanuvia$83$14,27312 claims
GSKTrelegy Ellipta, Arnuity Ellipta$632$10,71325 claims
Astellas Pharma US IncMyrbetriq$29$6,29714 claims
AbbVieSynthroid$1,830$2,95436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →